The association between use of non-injection drug implements and

The association between use of non-injection drug implements and hepatitis C virus antibody status in homeless and marginally housed persons in San Francisco. J Public Health 2012; 34: 330–339. 40  Harrell PT, Mancha BE, Petras H, Trenz RC, Latimer WW. Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors.

Drug Alcohol Depend 2012; 122: 220–227. 41  Nurutdinova D, Abdallah AB, Bradford S, O’Leary CC, Cottler LB. Risk factors associated with hepatitis C among female substance users enrolled in community-based HIV prevention studies. BMC Research Notes 2011; 4: 126. 42  Burton MJ, Olivier J, Mena L. Characteristics of hepatitis C virus coinfection in a human immunodeficiency virus-infected population with lower reported rates of injection drug use. Am J Med Sci 2009; 338: 54–56. 43  Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis AZD6244 datasheet 2001; 33: 562–569. 44  Sulkowski MS, Mehta SH, Torbenson MS et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21: 2209–2216. 45  Mohsen Doxorubicin nmr AH, Easterbrook PJ, Taylor C et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52: 1035–1040.

46  Bonnard P, Lescure FX, Amiel C et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat 2007; 14: 806–811. 47  Darby SC, Ewart D, Giangrande PL et al. Mortality from liver cancer and liver disease in haemophiliac men and boys in the UK given blood products

contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation. Lancet 1997; 350: 1425–1431. 48  Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 2007; 46: 613–619. 49  Macias J, Berenguer J, Japon MA et al. Fast fibrosis progression between repeated liver biopsies in Adenosine patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50: 1056–1063. 50  Verma S, Goldin RD, Main J. Hepatic steatosis in patients with HIV-hepatitis C virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis? BMC Res Notes 2008; 1: 46. 51  Ragni MV, Nalesnik MA, Schillo R, Dang Q et al. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 2009; 15: 552–558. 52  Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74–80. 53  Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD.

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>